SLC2A1 and prostate cancer: In humans, the upregulation in the expression of GLUT1 and GLUT3 has been observed in the majority of cancers (e.g., lung, brain, breast, bladder, cervical, colorectal, esophageal, hepatocellular, ovarian, renal cell, pancreatic, and prostate cancers) and has been linked to poor survival and tumor aggressiveness [10, 47, 48].